Advertisement
Organisation › Details
Medicines for Malaria Venture (MMV)
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Its mission is to reduce the burden of malaria in disease-endemic countries by enabling discovery, development and delivery of new, effective and affordable antimalarial drugs. Since its foundation in 1999, MMV and partners have developed and brought forward seven new medicines. In addition, MMV has taken over the stewardship of two approved artemisinin-based combination therapies (ACTs) developed by Drugs for Neglected Diseases initiative (DNDi) and partners. Since 2009, over 1.5 million lives are estimated to have been saved by MMV co-developed drugs. MMV and partners manage a portfolio of 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled. The portfolio includes nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s success in research and access & product management comes from its 160 active global partnerships. Since its inception in 1999, MMV has built an extensive network of over 400 pharmaceutical, academic and endemic-country partners in more than 55 countries. MMV’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease. MMV’s work is only possible due to the support of our partners and committed donors. *
Start | 1999-01-01 established | |
Group | UN (United Nations) | |
Industry | antimalarial drug | |
Industry 2 | drug development | |
Person | Wells, Tim (Medicines for Malaria 201102 CEO) | |
Region | ALL | |
City | n. a. ALL | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Merck KGaA. (4/19/18). "Press Release: Merck, University of Cape Town and Medicines for Malaria Venture Join Forces to Feed the Antimalarial Pipeline". Darmstadt. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for UN (United Nations)
- [1] Merck KGaA. (4/19/18). "Press Release: Merck, University of Cape Town and Medicines for Malaria Venture Join Forces to Feed the Antimalarial Pipeline". Darmstadt....
- [2] Roche. (1/4/18). "Press Release: Roche Launches the cobas Plasma Separation Card to Increase Access to HIV testing for Patients Living in Remote Areas". Basel....
- [3] Global Antibiotic Research and Development Partnership (GARDP). (9/4/17). "Press Release: More than EUR 56 Million Raised to Fund Initiative to Fight Antibiotic Resistance". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top